In this review, we will share the recent place of autologous stem cell transplantation in myeloma will be discussed from pretransplant treatment to posttransplant.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Treating multiple myeloma with high-level dose chemotherapy supported by transplanted autologous stem cells is still the primary and appropriate therapeutic strategy in affected patients.
📊
Key Findings & Data:Today, although the responses have improved considerably, especially during the treatment with the induction of the combination of immunomodulatory medication and proteasome blockers, no treatment approach has taken autologous stem cell transplantation into the background.
💡
Conclusion & Impact:In this review, we will share the recent place of autologous stem cell transplantation in myeloma will be discussed from pretransplant treatment to posttransplant.
Treating multiple myeloma with high-level dose chemotherapy supported by transplanted autologous stem cells is still the primary and appropriate therapeutic strategy in affected patients. Today, although the responses have improved considerably, especially during the treatment with the induction of the combination of immunomodulatory medication and proteasome blockers, no treatment approach has taken autologous stem cell transplantation into the background. In this review, we will share the recent place of autologous stem cell transplantation in myeloma will be discussed from pretransplant treatment to posttransplant.
Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086-107
Offidani M, Corvatta L, More S, Manieri MV, Olivieri A. An update on novel multiple myeloma targets. Expert Rev Hematol. 2022;15(6):519-37
Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017;376(14):1311-20
Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009;84(12):1095-110
Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blade J, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117(23):6063-73
Arora S, Majhail NS, Liu H. Hematopoietic Progenitor Cell Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma in Contemporary Era. Clin Lymphoma Myeloma Leuk. 2019;19(4):200-5
Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, et al. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 1996;347(8998):353-7
Lemoli RM, Martinelli G, Zamagni E, Motta MR, Rizzi S, Terragna C, et al. Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. Blood. 2000;95(7):2234-9
Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D, et al. Autotransplants in multiple myeloma: what have we learned? Blood. 1996;88(3):838-47
Anderlini P, Donato M, Lauppe MJ, Huh YO, Martin TG, Chan KW, et al. A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. Br J Haematol. 2000;109(4):770-2
Schmitt M, Hoffmann JM, Lorenz K, Publicover A, Schmitt A, Nagler A. Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF. Vox Sang. 2016;111(2):178-86